Happy Holidays and New year from the EMDB! Please be advised that the EMDB team will be operating at reduced capacity between December 15th - January 12th. With this in mind we would ask that you be prepared for longer reply times through both our helpdesk system and the OneDep deposition system. well done on a productive 2025, wishing you all the best and we will see you in 2026!

EMD-16279

Single-particle
3.11 Å
EMD-16279
3D View Gallery
Deposition: 06/12/2022
Map released: 24/01/2024
Last modified: 13/11/2024
Overview 3D View Sample Experiment Validation Additional data Links
Overview 3D View Sample Experiment Validation Additional data Links

EMD-16279
Download
3D volume (map.gz) Experimental metadata (xml) Experimental Metadata (cif.gz)
Map-only Validation report (pdf.gz) Map-only Validation report (cif.gz) Map-only Validation report (xml.gz)
Map and PDB model 8bw0 summary report (pdf.gz) Map and 8bw0 FULL report (pdf.gz)
EMICSS annotations (xml)

Structure of CEACAM5 A3-B3 domain in Complex with Tusamitamab Fab

EMD-16279

Single-particle
3.11 Å
EMD-16279
3D View Gallery
Deposition: 06/12/2022
Map released: 24/01/2024
Last modified: 13/11/2024
Overview 3D View Sample Experiment Validation Additional data Links
Sample Organism: Homo sapiens, Mus sp.
Sample: hCEACAM5-A3B3-Tusamitamab Fab complex
Fitted models: 8bw0

Deposition Authors: Kumar A , Bertrand T, Rapisarda C, Rak A
Structural insights into epitope-paratope interactions of a monoclonal antibody targeting CEACAM5-expressing tumors.
Kumar A , Duffieux F , Gagnaire M, Rapisarda C, Bertrand T, Rak A
(2024) Nat Commun , 15 , 9377 - 9377
PUBMED: 39477960
DOI: doi:10.1038/s41467-024-53746-9
ISSN: 2041-1723
Grant Support: